ClinicalTrials.gg
Not yet recruitingNCT07440238CORSARUpdated Feb 27, 2026

Evaluation of the Efficacy of Corticosteroids in Septic Arthritis in Adults

A Phase 2 interventional study of oral prednisone or placebo at a dose of 60 mg per day for 7 days in Septic Arthritis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Arthritis, Infectious with a site in France — 3 open to participants now, 4 under way, none of them phase 3. Arthritis, Infectious · France.

Started
2026
the only one that year
Phase 2
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
4 of 13
Assistance Publique - Hôpitaux de Paris

Among the 13 studies in Arthritis, Infectious with a site in France, this one is the only one that started in 2026, is the only one in phase 2, and was the 13th registered.

Arthritis, Infectious

51 studies on the registry are indexed under Arthritis, Infectious; 12 are open to participants now.

Browse Arthritis, Infectious studies →

Open to participants now

3 of the 13 studies in Arthritis, Infectious with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 7 Arthritis, Infectious studies recruiting now, 2 set no upper age limit and 5 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Arthritis, Infectious with a site in France, or all of them as a file.
02

Study summary

Septic arthritis is a severe infection associated with significant morbidity and mortality. Despite eradication of the microorganisms, persistent inflammation may lead to substantial long-term functional joint sequelae. The use of corticosteroids could reduce this inflammation, thereby improving functional joint outcomes and facilitating first-line medical treatment. The hypothesis of this study is that corticosteroid administration, in addition to antibiotic therapy, reduces persistent inflammation and improves functional joint prognosis in adult patients with acute septic arthritis.

Read the detailed description

Septic arthritis is a severe infection with a mortality rate of 10-15% and morbidity up to 25% due to rapid joint destruction. Despite antibiotic treatment, persistent intra-articular inflammation increases the risk of long-term joint damage. Standard care includes antibiotics and joint drainage, either surgically (arthrotomy or arthroscopy) or by repeated bedside aspiration. Surgery carries risks of nosocomial infections and complications, and aspirations are not always feasible.

Corticosteroids are currently not recommended in adult septic arthritis due to concerns that their anti-inflammatory effects might worsen infection. However, corticosteroids have shown benefits in other infections, improving outcomes in meningitis and pneumonia. Animal studies suggest that host inflammatory responses, particularly activation of CD4+ lymphocytes and macrophages, drive joint damage, and corticosteroids reduce this inflammation, preserving cartilage.

In children with septic arthritis, corticosteroids have been shown to reduce long-term joint damage, symptom duration, and hospital stay without increasing infection risk. To date, no randomized controlled trials have evaluated corticosteroids in adult septic arthritis.

This study aims to assess the efficacy and safety of adjunctive corticosteroid therapy with antibiotics in adults with septic arthritis, focusing on reducing joint sequelae, pain, hospital stay, and surgical interventions.

03

Conditions studied

  • Septic Arthritis

Browse trials for

Keywords

  • Articular prognosis
  • Corticosteroid
  • Acute septic arthritis
  • Antibiotic therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Documented septic arthritis (microorganism identified intra-articularly by culture or PCR, or by turbid synovial fluid with positive Gram stain, or positive blood cultures)
  • Effective antibiotic therapy initiated within ≤ 3 days
  • Effective for women of childbearing age during treatment period
  • Signed
  • Affiliation to the French national health insurance system
  • Ability to read, write, and understand French

Exclusion criteria

Exclusion Criteria:

  • Polyarticular septic arthritis (≥ 2 joints)
  • Septic arthritis of small joints (e.g., fingers: proximal interphalangeal joint (PIP), distal interphalangeal joints (DIP), MetaCarpoPhalangeal (MCP); toes: MTP)
  • Systemic sclerosis
  • Pyomyositis
  • Diabetic foot infection
  • Current therapy for another indication
  • Inability to take oral medication
  • to corticosteroids
  • Associated endocarditis
  • Presence of prosthetic joint or osteosynthesis material in the affected joint
  • Septic shock
  • Severe soft tissue wound overlying the joint
  • Aplastic chemotherapy
  • Neutropenia (defined as neutrophils \< 500/mm³)
  • Mycobacterial infection
  • Fungal infection
  • Sickle cell disease
  • Current pregnancy
  • Breastfeeding women
  • Patients under legal protection (e.g., guardianship)
  • Participation in another interventional clinical trial
  • Uncontrolled diabetes
  • Unstable psychiatric disorders
  • Adults unable to provide
  • Contraindication to corticosteroid therapy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Prednisone 60 mg/day for 7 days.

    Drug: oral prednisone or placebo at a dose of 60 mg per day for 7 days

  • Placebo comparator
    Control group

    Placebo of prednisone 60 mg/day for 7 days.

    Drug: oral prednisone or placebo at a dose of 60 mg per day for 7 days

Interventions

  • Drugoral prednisone or placebo at a dose of 60 mg per day for 7 days

    oral prednisone or placebo at a dose of 60 mg per day for 7 days

06

What researchers measure

Primary outcomes

  1. To assess the effect of adjunctive corticosteroid therapy added to standard antibiotic treatment on functional joint outcomes at 24 weeks in adult patients with acute septic arthritis.

    This outcome will be assessed using the total WOMAC score (Western Ontario and McMaster Universities Osteoarthritis Index) for lower limb involvement (hip, knee, or ankle joints). Scores range from 0 to 96 for the total WOMAC where 0 represents the best health status and 96 the worst possible status.

    Time frame: 24 weeks

  2. To assess the effect of adjunctive corticosteroid therapy added to standard antibiotic treatment on functional joint outcomes at 24 weeks in adult patients with acute septic arthritis.

    For upper limb involvement (shoulder, elbow, or wrist joints), the QuickDASH score (Disabilities of the Arm, Shoulder and Hand) will be used. Scores are calculated only for responses with at least 10 of the 11 items completed and transformed to a scale of 0-100, with higher scores indicating greater disability

    Time frame: 24 weeks

Secondary outcomes

  1. To evaluate the effect of corticosteroids on joint range of motion.

    Joint flexion and extension measured at weeks 1, 6, and 24 using a goniometer. Presence of flexion contracture (defined as incomplete extension) at 3 months, assessed only for septic arthritis of the hip and knee.

    Time frame: 1, 6, and 24 weeks

  2. To assess joint-related complications.

    Any complication assessed by radiological examination of the joint at week 24.

    Time frame: 24 weeks

  3. To determine whether corticosteroid administration affects the need for surgical intervention.

    Number of surgical interventions between randomization and week 24.

    Time frame: 24 weeks

  4. To evaluate whether corticosteroids modify the duration of antibiotic therapy.

    Duration of antibiotic therapy.

    Time frame: 24 weeks

  5. To assess the impact of corticosteroids on length of hospital stay.

    Length of hospital stay

    Time frame: 24 weeks

  6. To evaluate the effect of corticosteroids on pain.

    Pain assessed by Visual Analog Scale (VAS) at weeks 1, 6, and 24. range of scores from 0-10. A higher score indicates greater pain intensity

    Time frame: 24 weeks

  7. To assess the effect of corticosteroids on overall mortality.

    Overall mortality.

    Time frame: 24 weeks

  8. To evaluate the impact of corticosteroids on systemic inflammation.

    Biological inflammatory markers measured at weeks 1, 6, and 24.

    Time frame: 24 weeks

  9. To assess the effect of corticosteroids on patient-reported recovery.

    Patient self-assessment of recovery on a 0 to 5 scale (0 = no improvement, 5 = full recovery) at weeks 1, 6, and 24.

    Time frame: 24 weeks

  10. To evaluate the impact of corticosteroids on quality of life.

    Quality of life assessed by the EQ-5D-5L questionnaire at week 24.

    Time frame: 24 weeks

  11. To assess corticosteroid tolerance, including glycemic control and neuropsychiatric effects.

    All adverse effects and side effects, particularly glycemic control and neuropsychiatric effects, monitored through patient self-surveillance.

    Time frame: 24 weeks

07

Study locations

1 site
  • Hopital Robert Ballanger
    Aulnay-sous-Bois, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Sep 2026, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 27, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07440238
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Feb 27, 2026

Study contacts

Benjamin ROSSI, PhD
Contact
benjamin.rossi@ght-gpne.fr
+33 1 45 21 37 58

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion